The Stanford Hospital Heart Transplant Program has established a
comprehensive Quality and Clinical Effectiveness Program to improve
patient outcomes and satisfaction after undergoing heart
transplantation. We monitor hospital length of stay,
re-hospitalization rates, acute rejection rates, patient satisfaction
scores, and national
quality data from the University
HealthSystem Consortium to help us identify areas for
improvement and to monitor the effectiveness of our quality
Understanding the data
Source: UHC Comparison: 47 UHC members in UHC's Clinical Outcomes Report for Product Line of Heart Transplant or Implant of Heart Assist System
Many patients referred to Stanford Health Care for heart
transplantation are very sick and may have other medical conditions or
heart failure complications that decrease their chances for survival
after a heart transplant. The mortality Observed to Expected (O/E)
ratio compares patients' actual mortality rates to their expected
mortality rates--which take into account the severity of a patient's
illness. An O/E ratio of 1.0 indicates that the observed mortality
rate equaled the expected mortality rate based on patients' level of
illness, while a lower O/E mortality ratio means that more patients
survived than were expected due to the severity of their illness. The
O/E mortality ratio among patients undergoing heart transplantation at
Stanford has been declining steadily since 2009.
Extending our commitment to quality
The Heart Transplant Quality Council is a multidisciplinary
committee consisting of cardiologists, cardiothoracic surgeons,
advanced practice nurses, nurse coordinators, patient care unit
managers, social workers and other members of the heart transplant
team who meet monthly to monitor and address quality data and patient
adverse events, and to oversee the program's quality initiatives. Some
of the quality initiatives being implemented by the Quality Council to
improve survival and patient satisfaction after a heart transplant include:
Updating immunosuppressive medications to incorporate the use
of newer drugs with more specific action on immune cells and to
decrease the use of corticosteroids, which can cause rapid weight
gain, increase susceptibility to infection and worsen control of
blood glucose levels in diabetic patients.
patients with consultative care by specialized heart transplant
cardiologists immediately after transplant surgery.
Developing a clinical pathway to establish clear goals of care
for patients recovering from their heart transplant surgeries. These
efforts will improve coordination of care among physicians, nurses,
and other team members involved in the patient's hospital stay.
Establishing a dedicated cell phone number for patients to reach
the on-call heart transplant physician, 24 hours a day, 7 days a
week, in case of medical emergencies.
This unusual procedure, known as a "domino" transplant, occurs when one recipient receives a heart-lung transplant from a deceased donor, while the existing healthy heart of the heart-lung recipient is given to a second patient. The rare procedure has only been performed eight times at Stanford, last in 1994.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.